Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in a Case of Concurrent Neuroendocrine Tumors and Meningioma: Achieving Two Things in a Single Action

We present a partial response of peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTATATE in a case of concurrent neuroendocrine tumors (NETs) and meningioma. In addition to the valuable role of PRRT in inoperable NETs, it has been demonstrated that this treatment can be a promising therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Assadi, Majid, Rekabpour, Seyed Javad, Amini, Abdullatif, Dadgar, Habibollah, Nemati, Reza, Gholamrezanezhad, Ali, Nabipour, Iraj, Jafari, Esmail, Ahmadzadehfar, Hojjat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2021
Materias:
Interesting Image
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185482/
https://www.ncbi.nlm.nih.gov/pubmed/34082512
http://dx.doi.org/10.4274/mirt.galenos.2020.69783
_version_ 1783704796361916416
author Assadi, Majid
Rekabpour, Seyed Javad
Amini, Abdullatif
Dadgar, Habibollah
Nemati, Reza
Gholamrezanezhad, Ali
Nabipour, Iraj
Jafari, Esmail
Ahmadzadehfar, Hojjat
author_facet Assadi, Majid
Rekabpour, Seyed Javad
Amini, Abdullatif
Dadgar, Habibollah
Nemati, Reza
Gholamrezanezhad, Ali
Nabipour, Iraj
Jafari, Esmail
Ahmadzadehfar, Hojjat
author_sort Assadi, Majid
collection PubMed
description We present a partial response of peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTATATE in a case of concurrent neuroendocrine tumors (NETs) and meningioma. In addition to the valuable role of PRRT in inoperable NETs, it has been demonstrated that this treatment can be a promising therapy for progressive meningioma, especially in patients with low grade and refractory to standard regime.
format Online
Article
Text
id pubmed-8185482
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-81854822021-06-17 Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in a Case of Concurrent Neuroendocrine Tumors and Meningioma: Achieving Two Things in a Single Action Assadi, Majid Rekabpour, Seyed Javad Amini, Abdullatif Dadgar, Habibollah Nemati, Reza Gholamrezanezhad, Ali Nabipour, Iraj Jafari, Esmail Ahmadzadehfar, Hojjat Mol Imaging Radionucl Ther Interesting Image We present a partial response of peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTATATE in a case of concurrent neuroendocrine tumors (NETs) and meningioma. In addition to the valuable role of PRRT in inoperable NETs, it has been demonstrated that this treatment can be a promising therapy for progressive meningioma, especially in patients with low grade and refractory to standard regime. Galenos Publishing 2021-06 2021-06-03 /pmc/articles/PMC8185482/ /pubmed/34082512 http://dx.doi.org/10.4274/mirt.galenos.2020.69783 Text en ©Copyright 2021 by Turkish Society of Nuclear Medicine | Molecular Imaging and Radionuclide Therapy published by Galenos Yayınevi. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Interesting Image
Assadi, Majid
Rekabpour, Seyed Javad
Amini, Abdullatif
Dadgar, Habibollah
Nemati, Reza
Gholamrezanezhad, Ali
Nabipour, Iraj
Jafari, Esmail
Ahmadzadehfar, Hojjat
Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in a Case of Concurrent Neuroendocrine Tumors and Meningioma: Achieving Two Things in a Single Action
title Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in a Case of Concurrent Neuroendocrine Tumors and Meningioma: Achieving Two Things in a Single Action
title_full Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in a Case of Concurrent Neuroendocrine Tumors and Meningioma: Achieving Two Things in a Single Action
title_fullStr Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in a Case of Concurrent Neuroendocrine Tumors and Meningioma: Achieving Two Things in a Single Action
title_full_unstemmed Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in a Case of Concurrent Neuroendocrine Tumors and Meningioma: Achieving Two Things in a Single Action
title_short Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in a Case of Concurrent Neuroendocrine Tumors and Meningioma: Achieving Two Things in a Single Action
title_sort peptide receptor radionuclide therapy with (177)lu-dotatate in a case of concurrent neuroendocrine tumors and meningioma: achieving two things in a single action
topic Interesting Image
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185482/
https://www.ncbi.nlm.nih.gov/pubmed/34082512
http://dx.doi.org/10.4274/mirt.galenos.2020.69783
work_keys_str_mv AT assadimajid peptidereceptorradionuclidetherapywith177ludotatateinacaseofconcurrentneuroendocrinetumorsandmeningiomaachievingtwothingsinasingleaction
AT rekabpourseyedjavad peptidereceptorradionuclidetherapywith177ludotatateinacaseofconcurrentneuroendocrinetumorsandmeningiomaachievingtwothingsinasingleaction
AT aminiabdullatif peptidereceptorradionuclidetherapywith177ludotatateinacaseofconcurrentneuroendocrinetumorsandmeningiomaachievingtwothingsinasingleaction
AT dadgarhabibollah peptidereceptorradionuclidetherapywith177ludotatateinacaseofconcurrentneuroendocrinetumorsandmeningiomaachievingtwothingsinasingleaction
AT nematireza peptidereceptorradionuclidetherapywith177ludotatateinacaseofconcurrentneuroendocrinetumorsandmeningiomaachievingtwothingsinasingleaction
AT gholamrezanezhadali peptidereceptorradionuclidetherapywith177ludotatateinacaseofconcurrentneuroendocrinetumorsandmeningiomaachievingtwothingsinasingleaction
AT nabipouriraj peptidereceptorradionuclidetherapywith177ludotatateinacaseofconcurrentneuroendocrinetumorsandmeningiomaachievingtwothingsinasingleaction
AT jafariesmail peptidereceptorradionuclidetherapywith177ludotatateinacaseofconcurrentneuroendocrinetumorsandmeningiomaachievingtwothingsinasingleaction
AT ahmadzadehfarhojjat peptidereceptorradionuclidetherapywith177ludotatateinacaseofconcurrentneuroendocrinetumorsandmeningiomaachievingtwothingsinasingleaction

Ejemplares similares